What are the key takeaways from this Pathfinders in Biopharma episode?

Key insights include: **Universal flu protection gap:** Over 50 million high-risk or immunocompromised Americans fail to mount adequate responses to flu vaccines, creating a population entirely unserved by current prevention tools. CD388 bypasses immune response requirements by functioning as a direct antiviral, not a vaccine.; **Neuraminidase targeting strategy:** CD388 targets a universally conserved active site on neuraminidase that remains identical across all influenza strains year after year. This eliminates the annual strain-guessing problem that caused vaccine mismatch during the most severe flu season in 17 years.; **Phase 2b enrollment execution:** Cidara fully enrolled a 5,000-subject Phase 2b trial within 10 weeks, running September through December 2024 with a 40-person team. The trial coincided with a historically severe flu season, increasing the statistical likelihood of generating meaningful efficacy data.

What did A Single Dose discuss on Pathfinders in Biopharma?

Cidara Therapeutics CEO Jeff Stein discusses CD388, a single-dose antifungal-to-antiviral platform molecule targeting neuraminidase to deliver universal influenza protection across all strains, including for 50 million immunocompromised Americans who cannot respond to conventional vaccines. Key topics include: **Universal flu protection gap:** Over 50 million high-risk or immunocompromised Americans fail to mount adequate responses to flu vaccines, creating a population entirely unserved by current prevention tools. CD388 bypasses immune response requirements by functioning as a direct antiviral, not a vaccine.; **Neuraminidase targeting strategy:** CD388 targets a universally conserved active site on neuraminidase that remains identical across all influenza strains year after year. This eliminates the annual strain-guessing problem that caused vaccine mismatch during the most severe flu season in 17 years..

How long is this episode of Pathfinders in Biopharma?

This episode is 12 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Pathfinders in Biopharma

Cidara’s pursuit of universal flu protection with a single dose

July 11, 2025

12 min episode · 2 min read

A Single Dose

Episode

12 min

Read time

2 min

Topics

Relationships, Fundraising & VC, Leadership

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Universal flu protection gap: Over 50 million high-risk or immunocompromised Americans fail to mount adequate responses to flu vaccines, creating a population entirely unserved by current prevention tools. CD388 bypasses immune response requirements by functioning as a direct antiviral, not a vaccine.
✓Neuraminidase targeting strategy: CD388 targets a universally conserved active site on neuraminidase that remains identical across all influenza strains year after year. This eliminates the annual strain-guessing problem that caused vaccine mismatch during the most severe flu season in 17 years.
✓Phase 2b enrollment execution: Cidara fully enrolled a 5,000-subject Phase 2b trial within 10 weeks, running September through December 2024 with a 40-person team. The trial coincided with a historically severe flu season, increasing the statistical likelihood of generating meaningful efficacy data.
✓Reclaiming partnership rights: After J&J exited infectious disease in 2023, Cidara raised a $240 million PIPE financing to outcompete large pharma companies and reacquire full global rights to CD388 with zero royalty obligations, shifting from partner-dependent to fully independent development.

What It Covers

Cidara Therapeutics CEO Jeff Stein discusses CD388, a single-dose antifungal-to-antiviral platform molecule targeting neuraminidase to deliver universal influenza protection across all strains, including for 50 million immunocompromised Americans who cannot respond to conventional vaccines.

Key Questions Answered

•Universal flu protection gap: Over 50 million high-risk or immunocompromised Americans fail to mount adequate responses to flu vaccines, creating a population entirely unserved by current prevention tools. CD388 bypasses immune response requirements by functioning as a direct antiviral, not a vaccine.
•Neuraminidase targeting strategy: CD388 targets a universally conserved active site on neuraminidase that remains identical across all influenza strains year after year. This eliminates the annual strain-guessing problem that caused vaccine mismatch during the most severe flu season in 17 years.
•Phase 2b enrollment execution: Cidara fully enrolled a 5,000-subject Phase 2b trial within 10 weeks, running September through December 2024 with a 40-person team. The trial coincided with a historically severe flu season, increasing the statistical likelihood of generating meaningful efficacy data.
•Reclaiming partnership rights: After J&J exited infectious disease in 2023, Cidara raised a $240 million PIPE financing to outcompete large pharma companies and reacquire full global rights to CD388 with zero royalty obligations, shifting from partner-dependent to fully independent development.

Notable Moment

Stein revealed that despite widespread concern about FDA leadership disruptions, Cidara has experienced no regulatory delays and has actually seen faster-than-expected agency interactions, contradicting the prevailing anxiety across the biopharma sector.

Know someone who'd find this useful?